Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 02 2020
01 02 2020
Historique:
entrez:
27
12
2019
pubmed:
27
12
2019
medline:
20
1
2021
Statut:
ppublish
Résumé
: In the ADVANCE study of first-line treatment, there were 48 participants with HIV RNA at least 50 copies/ml in the week 48 window who had subsequent follow-up data available with no change in randomized treatment. More participants achieved virological re-suppression in the TAF/FTC+DTG and TDF/FTC+DTG arms (26/34, 76%) than on TDF/FTC/EFV (6/14 = 43%; P = 0.0421). It is unclear whether participants with HIV RNA at least 50 copies/ml at week 48 should be termed 'virological failures' on integrase inhibitor-based treatment.
Identifiants
pubmed: 31876594
doi: 10.1097/QAD.0000000000002422
pii: 00002030-202002010-00019
doi:
Substances chimiques
HIV Integrase Inhibitors
0
RNA, Viral
0
Types de publication
Letter
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
321-324Références
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med [Internet] 2000; 133:21–30.
Parienti J-J, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311–1316.
Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med 2016; 13:e1002183.
Hill A, Sabin C. Designing and interpreting HIV noninferiority trials in naive and experienced patients. AIDS 2008; 22:913–921.
FDA, CDER. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. 2015. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. [Accessed 20 August 2019]
Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B, et al. Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: Operational issues. Mor O, editor. PLoS One 2019; 14:e0211326.
Etoori D, Ciglenecki I, Ndlangamandla M, Edwards CG, Jobanputra K, Pasipamire M, et al. Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland. J Int AIDS Soc 2018; 21:e25194.
Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive nonnucleoside reverse transcriptase inhibitor-based regimen. AIDS 2008; 22:2279–2289.
Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16:1039–1044.
Vandenhende M-A, Ingle S, May M, Chene G, Zangerle R, et al. Antiretroviral Therapy Cohort Collaboration (ART-CC). Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS 2015; 29:373–383.
Joya C, Won SH, Schofield C, Lalani T, Maves RC, Kronmann K, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis 2019; [Epub ahead of print]. [Accessed 20 August 2019].
Hermans LE, Moorhouse M, Carmona S, Grobbee DE, Hofstra LM, Richman DD, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis 2018; 18:188–197.
U.S. Department of Health and Human Services. Plasma HIV-1 RNA (viral load) and CD4 count monitoring | laboratory testing | adult and adolescent ARV | AIDSinfo. AIDSInfo. 2014 [cited 24 September 2019]. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/458/plasma-hiv-1-rna--viral-load--and-cd4-count-monitoring. [Accessed 20 August 2019].
Walmsley S, Baumgerten A, Berenguer J, Felizarta F, Florence E, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr 2015; 70:515–519.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, noninferior. Lancet 2019; 393:143–155.
U.S. Department of Health and Human Services. Management of the treatment-experienced patient. Definition of virologic failure. AIDSInfo. [cited 2019 Aug 2]. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/15/virologic-failure-and-suboptimal-immunologic-response. [Accessed 10 September 2019].
Wainberg MA, Han Y-S. Will drug resistance against dolutegravir in initial therapy ever occur?. Front Pharmacol 2015; 6:90.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 2019; 381:803–815.
Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev 2019; 17:56–64.